title: Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
abstract: Tuberculosis (TB) is a serious and potentially fatal disease caused by Mycobacterium tuberculosis (M. tb). The occurrence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tb is a significant public health concern because most of the anti-TB drugs that have been in use for over 40 years are no longer effective for the treatment of these infections. Recently, new anti-TB lead compounds such as cyclomarin A, lassomycin, and ecumicin, which are cyclic peptides from actinomycetes, have shown potent anti-TB activity against MDR and XDR M. tb as well as drug-susceptible M. tb in vitro. The target molecule of these antibiotics is ClpC1, a protein that is essential for the growth of M. tb. In this review, we introduce the three anti-TB lead compounds as potential anti-TB therapeutic agents targeting ClpC1 and compare them with the existing anti-TB drugs approved by the US Food and Drug Administration.
authors.affiliation: Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Gyeonggi-do, 17058, South Korea.
authors.forename: Hanki
authors.initials: H
authors.lastname: Lee
authors.affiliation: Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Gyeonggi-do, 17058, South Korea. jwsuh@mju.ac.kr.|Division of Biosciences and Bioinformatics, College of Natural Science, Myongji University, Yongin, Gyeonggi-do, 17058, South Korea. jwsuh@mju.ac.kr.
authors.forename: Joo-Won
authors.initials: JW
authors.lastname: Suh
mesh_terms: D000995:Antitubercular Agents / Q000302:isolation & purification* / Q000494:pharmacology*; D001688:Biological Products / Q000737:chemistry*; D017277:Drug Approval; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000145:classification / Q000187:drug effects*; D010456:Peptides, Cyclic / Q000302:isolation & purification / Q000494:pharmacology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000382:microbiology*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000995:Antitubercular Agents; D001688:Biological Products; D010456:Peptides, Cyclic
keywords: Actinomycete; Anti-tuberculosis drugs; ClpC1; Tuberculosis